Kalaris Therapeutics, Inc. (KLRS) — 8-K Filings

8-K Filings (20)

• 8-K Filing — Dec 18, 2025
• 8-K Filing — Dec 17, 2025
• Kalaris Therapeutics Board Changes and Executive Compensation — Nov 3, 2025 Risk: low
  Kalaris Therapeutics, Inc. announced on October 28, 2025, the departure of Dr. Michael J. Yaszemski from its Board of Directors. The company also elected Dr. Da
• Kalaris Therapeutics Files 8-K on Financials — Aug 13, 2025 Risk: low
  Kalaris Therapeutics, Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition. The filing indicates the company's p
• Kalaris Therapeutics Files 8-K on Shareholder Nominations — Jun 20, 2025 Risk: medium
  Kalaris Therapeutics, Inc. filed an 8-K on June 20, 2025, reporting an event on June 19, 2025, related to shareholder nominations under Exchange Act Rule 14a-11
• Kalaris Therapeutics Files 8-K on Financials — May 14, 2025 Risk: low
  Kalaris Therapeutics, Inc. filed an 8-K on May 14, 2025, reporting on its results of operations and financial condition, as well as financial statements and exh
• Kalaris Therapeutics Adds Biotech Veteran to Board — Apr 16, 2025 Risk: low
  Kalaris Therapeutics, Inc. announced on April 10, 2025, the appointment of Dr. David L. Porter as a new member of its Board of Directors. Dr. Porter brings exte
• Kalaris Therapeutics Appoints New Director, Updates Executive Compensation — Apr 4, 2025 Risk: medium
  Kalaris Therapeutics, Inc. announced on April 3, 2025, changes in its board of directors and executive compensation. Specifically, Dr. David L. Brown was appoin
• Kalaris Therapeutics Reports Key Corporate Changes — Mar 18, 2025 Risk: medium
  Kalaris Therapeutics, Inc. filed an 8-K on March 18, 2025, reporting on several key events including the completion of an acquisition or disposition of assets,
• Allovir, Inc. Files 8-K: Officer Departures, Director Elections — Mar 12, 2025 Risk: medium
  On March 12, 2025, Allovir, Inc. filed an 8-K report detailing several key events. The company announced the departure of certain officers and directors, the el
• Allovir, Inc. Files 8-K on Security Holder Rights — Jan 15, 2025 Risk: medium
  On January 15, 2025, Allovir, Inc. filed an 8-K report detailing material modifications to the rights of its security holders and amendments to its articles of
• Allovir, Inc. Files 8-K on Security Holder Vote Matters — Jan 10, 2025 Risk: low
  On January 9, 2025, Allovir, Inc. filed an 8-K report indicating a submission of matters to a vote of security holders. The company, formerly known as ViraCyte,
• Allovir Appoints New Chief Medical Officer — Dec 20, 2024 Risk: medium
  Allovir, Inc. announced on December 19, 2024, the appointment of Dr. David M. Apelian as Chief Medical Officer. Dr. Apelian previously served as Executive Vice
• Allovir, Inc. Files 8-K with Material Agreement — Nov 8, 2024 Risk: medium
  On November 7, 2024, Allovir, Inc. entered into a Material Definitive Agreement. The filing also includes Regulation FD Disclosures and Financial Statements and
• Allovir, Inc. Terminates Material Definitive Agreement — Jul 2, 2024 Risk: medium
  Allovir, Inc. announced on July 1, 2024, the termination of a material definitive agreement. The company, formerly known as ViraCyte, Inc., is based in Waltham,
• Allovir Terminates Material Definitive Agreement — Jun 11, 2024 Risk: medium
  Allovir, Inc. announced on June 5, 2024, the termination of its Material Definitive Agreement with ViraCyte, Inc. The company, formerly known as ViraCyte, Inc.,
• Allovir, Inc. Files 8-K on Security Holder Vote Matters — Jun 7, 2024 Risk: low
  On June 6, 2024, Allovir, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The company, formerly known as ViraCyt
• Allovir Appoints New Directors, CMO Departs — Jun 3, 2024 Risk: medium
  Allovir, Inc. announced on May 31, 2024, the departure of its Chief Medical Officer, Dr. David Apelian. The company also reported the election of two new direct
• Allovir (ALVR) Receives Nasdaq Delisting Notice for Low Bid Price — Feb 12, 2024 Risk: high
  Allovir, Inc. (ALVR) announced on February 9, 2024, that it received a delisting notice from the Nasdaq Global Select Market because its common stock failed to
• Allovir Reports Costs from Exit/Disposal Activities on Jan 1 — Jan 4, 2024
  Allovir, Inc. filed an 8-K on January 4, 2024, reporting an event that occurred on January 1, 2024, related to "Cost Associated with Exit or Disposal Activities

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX